NCT00002233已完成2 期
A Phase II, 48-Week, Uncontrolled, Open-Label Study Designed to Evaluate the Safety and Efficacy of Quadruple Antiretroviral Therapy (EPIVIR, Abacavir, Amprenavir, and Indinavir) in Subjects Acutely Infected With HIV-1
Glaxo Wellcome3 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 3
研究概览
简要总结
The purpose of this study is to see if it is safe to give a combination of four anti-HIV drugs to patients recently infected with HIV who have never received anti-HIV treatment. The effects of this combination of drugs on the immune system and the level of HIV in the body are studied also. The four-drug combination includes lamivudine, abacavir, amprenavir, and indinavir.
详细描述
Patients receive a four-drug regimen consisting of two nucleoside reverse transcriptase inhibitors (3TC and abacavir) and two protease inhibitors (amprenavir and indinavir) for a minimum of 48 weeks. At specified time points, patients undergo physical assessments and efficacy evaluations which include plasma HIV-1 RNA measurements and CD4 cell counts. Depending on the immunologic and virologic status of the patient, further testing may be done to determine whether quadruple drug therapy can attain undetectable viral levels.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 15 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Concurrent Medication:
- •Allowed with caution and/or careful monitoring:
- •Drugs which may interact at CYP3A4 (e.g., alprazolam, carbamazepine, codeine, clarithromycin, dapsone, diazepam, diltiazem, erythromycin, estrogens, fluvastatin, glucocorticoids, imipramine, lidocaine, lovastatin, nifedipine, phenobarbital, phenytoin, simvastatin, and warfarin).
- •Drugs that inhibit cytosolic alcohol dehydrogenase (e.g., ethanol, disulfiram, chlorzoxazone, chlorpromazine, isoniazid, and chloral hydrate).
- •Drugs known to affect renal tubular secretion (e.g., probenecid or cimetidine), cause liver toxicity, or induce myelosuppression.
- •Patients must have:
- •Documented and confirmed acute HIV-1 infection.
- •No prior exposure to antiretroviral treatment.
- •Ability to comply with the investigational nature of the study for a minimum of 48 weeks.
- •Consent of parent or guardian if under the age of 18.
排除标准
- •Co-existing Condition:
- •Patients with the following symptoms and conditions are excluded:
- •A clinical diagnosis of AIDS, excluding CD4+ cell counts less than 200/mm
- •A serious medical condition such as diabetes, congestive heart failure, cardiomyopathy, or other cardiac dysfunction that, in the opinion of the investigator, compromises the safety of the patient.
- •Institutionalized or mentally disabled.
- •Inability to comply with the dosing schedule and protocol evaluations for reasons other than those specified.
- •Concurrent Medication:
- •Concurrent therapy with rifampin, rifabutin, terfenadine, astemizole, ketoconazole, itraconazole, cisapride, triazolam, midazolam, quinidine, amiodarone, and/or ergotamine/dihydroergotamine-containing regimens.
- •Foscarnet or therapy with other agents with documented in vitro or in vivo activity against HIV-
- •Medications known to induce or inhibit hepatic cytochrome P450 enzyme systems.
- •Vitamin E supplements.
- •Concurrent Treatment:
- •Dependence on blood transfusions.
- •Other investigational treatments.
- •Patients with the following prior conditions are excluded:
- •A history of clinically relevant pancreatitis or hepatitis within 6 months of study entry.
- •A history of inflammatory bowel disease or malignancy, intestinal ischemia, malabsorption, or other gastrointestinal dysfunction that might interfere with drug absorption or render the patient unable to take oral medication.
- •An unexplained fever above 38.5 Celsius for more than 14 days within 30 days of study entry.
- •A history of coagulopathy.
- •Prior Medication:
- •Prior exposure to antiretroviral therapy.
- •Therapy with immunomodulating agents such as systemic corticosteroids, interleukins, thalidomide, anti-cytokine agents or interferons, cytotoxic chemotherapeutic agents, or anti-oxidants within 30 days of study entry.
- •Prior Treatment:
- •- Radiation therapy within 30 days of study entry.
- •Risk Behavior:
- •Alcohol or illicit drug use which, in the opinion of the investigator, may interfere with ability to comply with the dosing schedule and protocol evaluations.
研究者
研究点 (3)
Loading locations...
相似试验
已完成
4 期
A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected AdultsHIV InfectionsNCT00004585Glaxo Wellcome40
已完成
2 期
Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease InhibitorsHIV InfectionsNCT00002361Merck Sharp & Dohme LLC30
已完成
1 期
Safety and Effectiveness of Giving Indinavir Plus Stavudine Plus Lamivudine to HIV-Infected ChildrenHIV InfectionsNCT00000901National Institute of Allergy and Infectious Diseases (NIAID)24
终止
2 期
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease InhibitorsHIV InfectionsNCT00002418Bristol-Myers Squibb25
已完成
2 期
A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment FailureHIV InfectionsNCT00000918National Institute of Allergy and Infectious Diseases (NIAID)300